Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin

• US 20060121004A1
• Filed: 12/07/2004
• Published: 06/08/2006
• Est. Priority Date: 12/07/2004
• Status: Abandoned Application

• Current Assignee: Francois Pattou, Merce Jourdain, Yann Echelard
• Original Assignee: Francois Pattou, Merce Jourdain, Yann Echelard
• Inventors: Echelard, Yann, Jourdain, Merce, Pattou, Francois
• Application Number:
  US11/006,055
• Publication Number:
  US 20060121004A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The use of antithrombin to improve the therapeutic efficacy of cell and organ transplantation.

Claims

1. A method of reducing complications and tissue rejection reactions seen upon a tissue and/or cell transplantation procedures comprising:

reversibly delivering a cell preparation graft to a mammal;

introducing a cell preparation graft comprising one or more cells and a biocompatible matrix into a tissue of a mammal;

removing said cell preparation graft or a portion thereof from said tissue; and

contemporaneously treating the mammal with an effective amount of antithrombin so as to reduce activation of the coagulation cascade.

6. The method of claim 1 further comprising treating the mammal prior to any said procedures with an amount of antithrombin sufficient to raise the normal circulating level of antithrombin in the blood stream by a minimum of 25%.

7. A method as recited in claim 1 wherein the amount of a Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day, wherein Formula I is comprised of an antithrombin compound and a carrier compound.

13. A method as recited in claim 7 wherein the amount of the Formula I compound is about 0.01 mg/kg/day to about 50 mg/kg/day of antithrombin.

16. The method of claim 1 wherein said tissue transplant procedure is selected from the following group of such procedures:

lung transplant;

islet cell transplant;

liver transplant;

heart transplant;

transplant coronary artery disease; and

, for the treatment of diabetes.

2-5. -5. (canceled)

8-12. -12. (canceled)

14-15. -15. (canceled)